Eli Lilly
Executive Summary
This appears to be erroneous data - Eli Lilly is a major US pharmaceutical company headquartered in Indianapolis, not a Chinese entity. Eli Lilly and Company is a Fortune 500 American pharmaceutical corporation founded in 1876, known for diabetes care, oncology, immunology, and neuroscience therapeutics. If evaluating partnerships with Eli Lilly's Chinese operations, BIOSECURE risk would be minimal given its US parent structure. This data requires immediate verification and correction.
Structure: Based on available data, this appears to be a misclassification of the major US pharmaceutical company Eli Lilly and Company. If referring to Eli Lilly's Chinese subsidiaries or operations, these would operate under standard WOFE (Wholly Owned Foreign Enterprise) structures typical of US pharma companies in China. Due diligence should focus on clarifying the actual entity in question.
Ownership & Shareholder Structure
Eli Lilly → Innovent Biologics
Lilly holds strategic equity stake in Innovent from $100M investment alongside licensing deal.
Innovent Biologics → Eli Lilly
Lilly-Innovent $1.4B+ long-running strategic collaboration.
Junshi Biosciences → Eli Lilly
Junshi toripalimab partnership — Lilly distributes in China.
Structure Therapeutics → Eli Lilly
Structure Therapeutics oral GLP-1 competes in Lilly's obesity market.
Adagene → Eli Lilly
Adagene SAFEbody platform collaboration with Eli Lilly for masked antibodies.
Terns Pharmaceuticals → Eli Lilly
Terns NASH/metabolic pipeline competes in Lilly metabolic market.
BIOSECURE Risk
If this refers to US-based Eli Lilly or its controlled Chinese subsidiaries, BIOSECURE risk is minimal due to US parent company control and compliance infrastructure
Key Exposures:
- •Potential data sharing with Chinese operations
- •Supply chain dependencies
- •Joint venture partnerships in China
Mitigation: As a major US pharma company, likely has established compliance frameworks for China operations
BD Intelligence
Therapeutic Areas:
Recent Deals: No reliable data available for assessment
Approach: Immediate data verification required before any BD engagement recommendations
Red Flags
- ⚠Fundamental data inconsistency - major US pharma company listed as Chinese entity
- ⚠No subsidiary or key personnel data available
- ⚠No recent corporate events recorded
- ⚠Data integrity concerns require immediate investigation
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 8
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.